---
title: Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease
nct_id: NCT05896579
overall_status: RECRUITING
phase: NA
sponsor: University of Colorado, Denver
study_type: INTERVENTIONAL
primary_condition: COPD
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05896579.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05896579"
ct_last_update_post_date: 2026-05-08
last_seen_at: "2026-05-12T06:58:59.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease

**NCT ID:** [NCT05896579](https://clinicaltrials.gov/study/NCT05896579)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** University of Colorado, Denver
- **Conditions:** COPD, Pulmonary Hypertension, Right Ventricular Dysfunction, Exercise, Exercise Training
- **Start Date:** 2023-08-22
- **Completion Date:** 2030-08
- **CT.gov Last Update:** 2026-05-08

## Brief Summary

This study plans to learn about heart function among individuals with chronic obstructive pulmonary disease (COPD). In particular, the investigators want to understand the different patterns of right ventricular response during rest and moderate- vs high-intensity exercise. By identifying patterns of right ventricular dysfunction, this study will help identify better treatments for patients with COPD in the future.

## Eligibility

- **Minimum age:** 40 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* COPD (determined by ratio of forced expiratory volume in 1 second to forced vital capacity \[FEV1/FVC\] \<0.7)
* Age \>= 40 years

Exclusion Criteria:

* Exacerbation of COPD in the 3 months prior to enrollment
* Change in COPD therapy in the 3 weeks prior to enrollment
* Requirement of \>6 LPM supplemental oxygen at rest
* Requirement of \>10 LPM supplemental oxygen with exertion
* Active/uncontrolled cardiovascular disease (e.g. hypertension with blood pressure \>150/100 despite antihypertensives; coronary artery disease with angina; left ventricular ejection fraction ≤40%; arrhythmia; pulmonic, mitral or aortic valvular abnormality greater than mild in severity; tricuspid regurgitation greater than moderate in severity)
* Volume overload (jugular vascular distension or greater than trace peripheral edema)
* World Health Organization Functional Class IV
* Known pulmonary hypertension with mean pulmonary artery pressure \>45 mmHg
* Untreated severe obstructive sleep apnea or obesity hypoventilation syndrome
* Active malignancy (other than skin)
* Medical conditions that limit exercise on an upright stationary bicycle (e.g. severe osteoarthritis, imbalance/gait instability, etc.)
* Pregnancy
* Body mass index \<18 or \>40
* Hematocrit \<25% or \>55%
* For invasive CPET, chronic anticoagulation that is unable to be held for the study visit
* For invasive CPET, forced expiratory volume in 1 second of \<20%
```

## Arms

- **COPD** (EXPERIMENTAL) — Participants will complete testing at rest and during moderate- and high-intensity exercise to identify patterns of right ventricular responses.

## Interventions

- **Exercise** (BEHAVIORAL) — After a brief warmup, participants will be asked to perform approximately 5 minutes of exercise at moderate intensity and then approximately 2 minutes of exercise at high intensity.

## Primary Outcomes

- **Right ventricular contractility measured by transthoracic echocardiography** _(time frame: Up to 1 hour)_ — Global longitudinal strain, measured in absolute percent

## Secondary Outcomes

- **Right ventricular contractility measured by conductance catheter** _(time frame: Up to 1 hour)_
- **Right ventricular systolic function measured by transthoracic echocardiography** _(time frame: Up to 1 hour)_
- **Right ventricular systolic function measured by transthoracic echocardiography** _(time frame: Up to 1 hour)_
- **Health-related quality of life by Short Form 36 (SF-36) questionnaire** _(time frame: Up to 1 hour)_
- **Maximum oxygen consumption (VO2max)** _(time frame: Up to 1 hour)_
- **Plasma acylcarnitines measured via ultra-high-performance liquid chromatography coupled to mass spectrometry** _(time frame: Up to 1 hour)_
- **Physical activity measured by activity monitor** _(time frame: 7 days)_

## Locations (1)

- University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of colorado anschutz medical campus|aurora|colorado|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05896579.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05896579*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*